Methods

Subjects
We have performed ECG at least once a year for all patients of the Institute for Adult Diseases Asahi Life Foundation, even for those without any cardiovascular diseases. The ECG laboratory has listed for some decades all cases with AF and for the present study, we selected from that database 75 patients who had been in sinus rhythm at the first visit to hospital from 1989 to 2001 and who had afterwards developed AF (or pAF). Most of these cases did not have signs or symptoms of valvular heart disease or ischemic heart disease. We checked the following information from the medical records: (1) sex, (2) age (years) at first ECG record of AF, (3) averaged ventricular response (V rate, beats/min) at the first-recorded AF, (4) cardiac symptoms at the first-recorded AF, including palpitation, shortness of breath, pulse irregularity and chest pain or discomfort, (5) HbA,C (%) just before (2.6±0.8 months) the first-recorded AF, (6) heart rate (beats/min) on the last ECG record with sinus rhythm just before (4.8±0.8 months) the first-recorded AF, (7) the difference between the averaged V rate at the first-recorded AF and heart rate on the last record of sinus rhythm, and (8) prescribed antiarrhythmic drugs at the first-recorded AF that may slow the AF rate and/or atrioventricular conduction, including -blockers (Vaughan Williams group II), procainamide, disopyramide (Ia), verapamil or diltiazem (IV). Patients on DM treatment or with HbA1c higher than 6.4% were considered as DM patients, for whom we additionally investigated the following: (9) the duration from the DM diagnosis to the first-recorded AF, (10) treatment for DM (insulin, oral drugs, or diet and exercise only), and (11) signs of DM neuropathy: paresthesia, hypasthesia and neurogenic bladder were recorded as subjective symptoms and hyporeflexia and It is well known that diabetes mellitus (DM) masks the cardiac symptoms during an ischemic heart attack, but there have not been reports of whether DM influences the subjective symptoms of atrial fibrillation (AF). The present study retrospectively assessed 65 patients who were revealed to be in sinus rhythm at their first visit to hospital and who had experienced episodes of AF (or paroxysmal AF) during the follow-up period. Compared with non-DM cases (n=50), DM patients (n=15) had a tendency to a more rapid heart rate in sinus rhythm (73±4 vs 66±2, p=0.07) and higher averaged ventricular response at the first-recorded episode of AF (111±7 vs 99±3, p=0.10). However, the ratio of symptomatic cases at first-recorded AF tended to be lower in DM cases (33% vs 58%, p=0.08). When patients with -blockers or other antiarrhythmic agents were excluded, the ratio of symptovibration sensory disturbance were the objective findings. Of the 75 selected cases, 10 were excluded: 8 did not have enough data about glucose tolerance, 1 was too young (25 years old) and 1 had junctional escaped beats at the onset of AF. Thus, we studied 65 cases in total.
Statistical Analysis
Values are expressed as means ± SE. Unpaired Student's t-tests were used to assess the differences between 2 groups. The chi-square test was used to examine differences in incidence. A p-value <0.05 was considered statistically significant.
Results
There was a male predominance in the present study (Table 1) , similar to previous reports of the prevalence of AF, 1, 6, 7 and this tendency did not change when we classified the cases into 2 groups, DM or non-DM.
Non-DM Cases
We evaluated 50 cases without DM (HbA1c 5.5±0.1%), first by classifying them by their cardiac symptoms at the first-recorded AF (Table 2) . Symptomatic patients had various complaints, including palpitation (11 cases), shortness of breath (3), pulse irregularity (8) and chest pain or discomfort (7) . According to the medical records, none of the asymptomatic cases had mentioned cardiac symptoms, even after shown the evidence of AF on their ECG records. There was no significant difference between the 2 groups in sex (male: 66% vs 81%, NS), age at the first-recorded AF (65±2 vs 64±3 years, NS) and the heart rate on the last ECG record of sinus rhythm before the first-recorded AF (66±3 vs 65±2 beats/min, NS). In addition, the ratio of cases with antiarrhythmic drugs was almost same in both groups (41 vs 48%, NS). However, the averaged ventricular rate (V rate) at the first-recorded AF, and the difference between the averaged V rate at the first-recorded AF and heart rate on the last record of sinus rhythm (∆heart rate) were significantly higher in the symptomatic group (V rate: symptomatic: 108±5, asymptomatic: 90±3 beats/min, p=0.006; ∆heart rate: symptomatic: 42±5, asymptomatic: 25±4 beats/min, p=0.01).
We next subdivided all the non-DM cases by the presence of prescribed antiarrhythmic drugs ( Table 2 ). These agents, including the Vaughan Williams group Ia (disopyramide, procainamide: 2 cases), II ( -blockers: 16), IV (verapamil, diltiazem; 3) or digitalis (3), decreased the V rate at the onset of AF (91±4 vs 106±5 beats/min, n=0.02), but did not change the ratio of symptomatic cases (55 vs 61%, NS).
DM Cases
Among the 15 patients with DM, 1 patient was on insulin therapy and 9 were taking oral DM drugs. The HbA1c value of all the DM cases (7.2±0.3%) was significantly higher than those of the non-DM cases (p<0.000001) ( Table 3 ). The DM group had tendencies to a lower ratio of cases with antiarrhythmic drugs (20 vs 44%, p=0.09), higher heart rate on the last sinus record (73±4 vs 66±2 beats/min, p=0.07) and higher V rate at the firstrecorded AF (111±7 vs 99±3 beats/min, p=0.10). Nevertheless, the ratio of symptomatic cases (palpitation 1, pulse irregularity 2, chest discomfort 2) was relatively lower in the DM group (33 vs 58%, p=0.08). When we excluded the patients with prescribed antiarrhythmic drugs (1 case with -blocker and 2 with Ia), there was no significant difference in the heart rate on the last sinus record and V rate at the first-recorded AF (sinus rate: DM: 73±5, non-DM: 67± 2 beats/min, NS; V rate: DM: 112±8, non-DM: 106± 5 beats/min, NS) (Table 3) . However, the ratio of symptomatic cases (palpitation 1, pulse irregularity 1, chest discomfort 1) was significantly lower in the DM group (25% vs 61%, p=0.04).
Finally, we classified the DM cases into symptomatic or asymptomatic (Table 4) . Although the former group had a significantly lower ratio of males (60% vs 100%, p=0.03), there was no significant difference between these 2 groups in heart rate on last sinus record (72±6 vs 74±6 beats/min, NS), age at the first-recorded AF (64±6 vs 67±4 years, NS) or V rate at the first-recorded AF (122±13 vs 105± 8 beats/min, NS). The ratio of cases with antiarrhythmic drugs was not lower in the symptomatic group (40% vs 10%, NS). In addition, the duration of DM or the value of HbA1c at the first-recorded AF was almost same in both groups (duration: symptomatic: 10.0±3.9, asymptomatic: 13.0±2.9 years, NS; HbA1C: symptomatic: 7.0±0.6, asymptomatic: 7.4±0.3%, NS). However, the ratio of cases with DM neuropathy was higher in the asymptomatic cases (subjective: symptomatic: 0, asymptomatic: 40%, p=0.10; subjective + objective: symptomatic: 0, asymptomatic: 70%, p=0.01) ( Table 4) . Patients with DM neuropathy in this study had a tendency toward a significant gender difference, but it did not reach statistical significance (Table 4) .
Discussion
We have shown that DM neuropathy may depress the cardiac symptoms caused by AF and to our knowledge, this is the first report of the influence of DM on the subjective symptoms of arrhythmia.
Cardiac Symptoms at First-Recorded Episode of AF and Antiarrhythmic Agents
Patients with AF usually complain of various symptoms, including palpitation, pulse irregularity or chest discomfort, but many of these symptoms generally become milder or disappear when the arrhythmia becomes permanent. Therefore, in the present study we evaluated only the symptoms at the first-recorded episode of AF.
Many of the symptoms of AF may be related to the rapid ventricular response. 1 In the present study, asymptomatic cases in the non-DM group had a lower V rate at the firstrecorded AF; however, it is very interesting that antiarrhythmic drugs, including -blockers, decreased the V rate by slowing the AF rate and/or atrioventricular conduction, but did not influence the incidence of cardiac complaints at the first-recorded AF. That may depend on the irregularity of the ventricular response, which cannot be controlled by those therapeutic agents. The absence of effective atrial contraction may be also related or some patients may be more sensitive to any chest symptoms, despite these medications, because they have already experienced some cardiac problems before the first time AF was objectively recorded on the ECG.
Influence of DM on the Cardiac Symptoms During the First-Recorded AF
Tachycardia is one of the cardiac symptoms by DM autonomic system disorders, 8, 9 and in the present cases of DM we also observed a tendency of higher heart rate in sinus rhythm and higher V rate at the first recorded AF. However, these findings disappeared when we excluded patients taking antiarrhythmic drugs, including -blockers, which were prescribed more frequently to non-DM cases. The result may reflect the possibly milder neurological impairment in the present DM patients, or the small sample number of this study.
The DM group had a significantly lower prevalence of cardiac symptoms at the first-recorded AF, despite the relatively higher V rate, which is very interesting because a correlation between V rate and symptoms at the first- recorded AF was found in non-DM cases. Moreover, the influence of DM is in contrast to that of the antiarrhythmic drugs, including -blockers, described earlier. Thus, DM might depress the cardiac symptoms of AF, not directly by influencing the impulse conducting system, but rather the neurological mechanisms that sense the changes in heart rhythm. Indeed, we demonstrated more DM neurological disorders in the asymptomatic group. It is known that in some patients the cardiac symptoms of an ischemic heart attack are masked (silent ischemia), particularly in those with DM. [2] [3] [4] 10 It is generally considered that peripheral neuropathy is the main reason for this phenomenon, although some investigators have indicated that the central nerve system may also play a role in silent ischemia. 10 The mechanism of the conversion from paroxysmal to chronic AF, which may decrease the cardiac symptoms, has not been fully elucidated yet. Some cases of persistent AF may be treated with drugs in order to control the V rate, which can decrease their cardiac complaints during chronic AF, although in the present study these agents did not change those symptoms at the onset of AF. In other cases there may be a higher perceptive threshold to the irregularity of the heart rhythm after a long period of AF. Similarly, DM neuropathy may decrease the sensitivity of the cardiac nerves and thus mask the rapidity or irregularity of the heart rhythm during the first-recorded AF.
We report the possibility of a gender difference in DM patients in the cardiac symptoms of the first-recorded AF. Women with AF are reportedly more sensitive to their own heart rhythm or chest symptoms, 6 but we did not find a significant gender difference in the non-DM cases in the cardiac symptoms at the first-recorded AF. However, from our results the prevalence of DM neuropathy might be higher in male patients. Progression of DM neuropathy may be influenced by hyperglycemia-induced oxidative stress, 11 which can be inhibited by antioxidant compounds, including estrogen. 12 Thus, female patients with DM may have less neurological impairment than males, 13 but in the present study the average age of the DM cases was 66±3 years old and the 2 female patients with DM were 81 and 69 years old, respectively, so it is likely that the effects of the sex hormone were slight. The possible gender difference in the prevalence of cardiac symptoms at the firstrecorded AF or DM neuropathy in this study may reflect the small sample number.
Clinical Implications
We have shown that DM, one of the strongest risk factors of atherosclerosis, tends to depress the cardiac symptoms of AF and thus, we recommend clinical physicians routinely check the ECG for all their DM patients. The arrhythmia, one of the major causes of cardiogenic thromboembolism, should be defibrillated earlier and prevented afterwards, especially in patients with DM. In addition, antiplatelet and/or anticoagulation therapy is also required to prevent cerebral vessel disease or other arterial diseases.
Study Limitations
First, we retrospectively checked the medical records and there was no advance standard to ask about subjective complaints or to check objective data. Therefore, some data, especially of the subjective symptoms, may depend on various factors in daily clinical practice. Non-cardiology physicians may not have carefully asked their patients about cardiac symptoms, and equally patients in non-cardiology clinics may not have mentioned those complaints to the doctor. On the other hand, cardiologists may not have carefully checked the neurological signs and symptoms of their patients with DM. Moreover, it is very hard, almost impossible, to definitely assign each symptom to AF.
Second, some patients with AF may have an underlying heart diseases, such as valvular heart disease, ischemic heart disease or cardiomyopathy, which may be related to the subjective symptoms of AF. 1 However, in this study we could not evaluate the role of underlying heart diseases because these diseases had not been fully assessed in the DM group.
Third, many of the medical records did not have detailed neurological findings, especially those from the outpatient clinics. Tests of peripheral nerve conduction velocity or the autonomic nerve system were performed at the firstrecorded AF in only a few DM cases. Therefore, we could not fully evaluate the relationship between the severity of DM neuropathy and the absence of cardiac symptoms at the first-recorded AF.
